
Report ID: UCMIG35D2208
SkyQuest Technology's Preimplantation genetic testing market size, share and forecast Report is based on the analysis of market data and Industry trends impacting the global Preimplantation Genetic Testing Market and the revenue of top companies operating in it. Market Size Data and Statistics are based on the comprehensive research by our Team of Analysts and Industry experts.
In 2018, the global market for Preimplantation Genetic Testing (PGT), encompassing both Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD), was valued at approximately USD 74.72 million. The market is on track for substantial growth, projected to sustain a compound annual growth rate (CAGR) of 6.2% throughout the forecast period. This growth trajectory is driven by a confluence of factors, notably advancements in assisted reproductive technologies and increasing awareness of genetic health risks. PGT holds a pivotal role in enabling prospective parents to screen embryos for genetic abnormalities before implantation, thereby enhancing the chances of successful pregnancies and reducing the risk of inherited disorders. As the medical landscape continues to evolve, the global Preimplantation Genetic Testing market is poised to shape the future of reproductive medicine and family planning strategies.
This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.
Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.
The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Health Care Services by segment aggregation, the contribution of the Health Care Services in Health Care Equipment & Services and vendor share.
To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.
REQUEST FOR SAMPLE
The market for Preimplantation Genetic Testing was estimated to be valued at US$ XX Mn in 2021.
The Preimplantation Genetic Testing Market is estimated to grow at a CAGR of XX% by 2028.
The Preimplantation Genetic Testing Market is segmented on the basis of PGD/PGS (Revenue, USD Million, 2014 - 2024), Application (Revenue, USD Million, 2014 - 2024), Regional (Revenue, USD Million, 2014 - 2024).
Based on region, the Preimplantation Genetic Testing Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
The key players operating in the Preimplantation Genetic Testing Market are , Illumina Inc. , Thermo Fisher Scientific, Inc. , Natera, Inc. , Bioarray S.L. , Good Start Genetics, Inc. , Laboratory Corporation of America Holdings , California Pacific Medical Center , Quest Diagnostics Incorporated , Reproductive Health Science Ltd. , CooperSurgical, Inc. , Genea Limited , IGENOMIX , Reproductive Genetic Innovations, LLC , F. Hoffmann-La Roche AG , CombiMatrix.".
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: UCMIG35D2208
sales@skyquestt.com
USA +1 351-333-4748